Report

Angel Yeast Publishes 2023 Corporate Social Responsibility Report

Retrieved on: 
Monday, April 29, 2024
CSR, Multimedia, Report, Social responsibility, Accreditation, Nature, Biotechnology, Safety, Carbon, Welfare, Fine chemical

SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has released its 2023 CSR Report (the "Report").

Key Points: 
  • SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has released its 2023 CSR Report (the "Report").
  • The Report highlights the company's mission and vision, advancements in international expansion, intelligent and digital strategies, patent development, social responsibility efforts, and initiatives for employee growth and development.
  • Additionally, Angel Yeast is committed to social welfare, demonstrated by passing the ECOVADIS social responsibility accreditation in December 2023.
  • In 2023, Angel Yeast invested 603 million yuan (USD 83.31 million) in R&D, marking a 12.5% increase from the previous year.

Angel Yeast Publishes 2023 Corporate Social Responsibility Report

Retrieved on: 
Monday, April 29, 2024
CSR, Report, Social responsibility, Accreditation, Nature, Biotechnology, Safety, Carbon, Welfare, Fine chemical

SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has released its 2023 CSR Report (the "Report").

Key Points: 
  • SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has released its 2023 CSR Report (the "Report").
  • The Report highlights the company's mission and vision, advancements in international expansion, intelligent and digital strategies, patent development, social responsibility efforts, and initiatives for employee growth and development.
  • Additionally, Angel Yeast is committed to social welfare, demonstrated by passing the ECOVADIS social responsibility accreditation in December 2023.
  • In 2023, Angel Yeast invested 603 million yuan (USD 83.31 million) in R&D, marking a 12.5% increase from the previous year.

FDA Roundup: April 26, 2024

Retrieved on: 
Friday, April 26, 2024
FDA, Lutetium (177Lu) oxodotreotide, Sale, Answer, Public, Report, Cosmetics, Syringe, Dietary supplement, News, Safety, DCM, Food, Research, Human services, GFI, Animal, Dilated cardiomyopathy, Cardinal Health, Commitment, Diabetes, Furosemide, Glomus tumor, Vaccine, Development, VFD, Osteoporosis, Novartis, BRAF, Inflammatory bowel disease, Tablet, Patient, Rheumatoid arthritis, Psoriasis, Heated tobacco product, Macular degeneration, Multimedia, Dog, Cancer, LGG, Food and Drug Administration, BRAF V600, Heart, Pharmaceutical industry

On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.

Key Points: 
  • On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.
  • The FDA expects this firm to fully address the violations described in the warning letter.
  • This represents the first FDA approval of a radioactive drug, or radiopharmaceutical, for pediatric patients 12 years of age and older with SSTR-positive GEP-NETs.
  • This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions.

General Meeting of Arbonia AG approves all motions

Retrieved on: 
Friday, May 3, 2024
Annual general meeting, Sale, Report, KPMG, Management, Mass meeting, Proxy, Financial statement, Consolidated, CHF

Arbon, 19 April 2024 – The shareholders of Arbonia AG approved all of the motions proposed by the Board of Directors at today’s General Meeting.

Key Points: 
  • Arbon, 19 April 2024 – The shareholders of Arbonia AG approved all of the motions proposed by the Board of Directors at today’s General Meeting.
  • At today’s 37th Annual General Meeting, Arbonia AG shareholders approved the Management Report of the Group, Financial Statements, Consolidated Financial Statement and Report on Non-financial Matters for the 2023 financial year.
  • This nominal value repayment would presumably be tax-free for the majority of Arbonia shareholders.
  • The independent proxy as well as the statutory auditor KPMG were confirmed in office until the next Annual General Meeting; in other words, for the 2024 financial year.

Metro Bank Holdings PLC: Publication of Annual Report and Accounts and Notice of 2024 Annual General Meeting

Retrieved on: 
Friday, May 3, 2024
Report, DA-88, Equiniti, Annual report, Form, Disclosure, Bank statement, Metrobank, Theo Parrish, AGM, National Storage, Cryptocurrency

This is the first Annual Report and Accounts for the Group since the insertion of a holding company in May 2023.

Key Points: 
  • This is the first Annual Report and Accounts for the Group since the insertion of a holding company in May 2023.
  • The Annual Report and Accounts for Metro Bank PLC will be published later in April 2024.
  • The AGM will be held at First Floor, One Southampton Row, London WC1B 5HA on Tuesday, 21 May 2024 at 09:00am.
  • 2023 Annual Report and Accounts; and
    Notice of Annual General Meeting to be held on 21 May 2024.

Cembra shareholders approve all proposals of the Board of Directors

Retrieved on: 
Friday, May 3, 2024
CHF, Annual, Cembra, Report, Annual report, Compensation, Proxy

Zurich, 24 April 2024 – The Annual General Meeting 2024 of the Swiss bank Cembra was held in Zurich today.

Key Points: 
  • Zurich, 24 April 2024 – The Annual General Meeting 2024 of the Swiss bank Cembra was held in Zurich today.
  • 304 shareholders attended the meeting, representing 14,665,422 registered shares (including the shares represented by the independent proxy) and 48.88% of the issued share capital, respectively.
  • All members of the Board of Directors proposed for re-election were confirmed for a further one-year term of office: Franco Morra (Chairman), Marc Berg, Thomas Buess, Susanne Klöss-Braekler and Monica Mächler.
  • Sandra Hauser was elected as new member of the Board of Directors.

EQS-News: Mayr-Melnhof Karton AG: MM reports first quarter 2024 results

Retrieved on: 
Friday, May 3, 2024
Report, Packaging and labeling, Press release, Pressure, Growth

In contrast, the Packaging division recorded a slight increase in results compared to the previous year, even though the margin was below the strong level of the 3rd and 4th quarter of 2023.

Key Points: 
  • In contrast, the Packaging division recorded a slight increase in results compared to the previous year, even though the margin was below the strong level of the 3rd and 4th quarter of 2023.
  • Against this background, the profit & cash protection programme, which has already been successfully implemented, and the measures to intensify market penetration will be systematically continued in 2024.
  • In particular, the development of sales prices will remain decisive for the earnings situation in 2024.”, underlines Oswald.
  • Please find the detailed Press Release and the Report for the first quarter of 2024 as well as the CEO Audio-Q&A-Webcast on our website: https://www.mm.group.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AXT, Inc. Investors to Inquire About Securities Class Action Investigation - AXTI

Retrieved on: 
Thursday, April 25, 2024
Titan, Report, IP, News, Advertising, Plaintiff, IPO, Public, AXT, Security (finance)

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24168 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Wolf Popper LLP Continues its Investigation on Behalf of Investors in Harmony Biosciences Holdings, Inc.

Retrieved on: 
Thursday, April 25, 2024
FDA, Report, News, Advertising, Patient, Scorpion, DSM-IV codes, Toxicity, Death

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing to investigate potential securities fraud claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. (“Harmony”) common stock (NASDAQ: HRMY).

Key Points: 
  • NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing to investigate potential securities fraud claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. (“Harmony”) common stock (NASDAQ: HRMY).
  • Harmony is a commercial and clinical stage drug company that focuses on therapies for patients with rare neurological diseases.
  • Wolf Popper has successfully recovered billions of dollars for defrauded investors.
  • Wolf Popper’s reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.

Comprehensive Network Surveillance and Optimization

Retrieved on: 
Wednesday, April 24, 2024
SS7, Signal-to-noise ratio, TRAU, SIP, PCAP, IMS, Phonation, ANSI, Quality of service, ITU, Table, Lite, IP, SONET, CDR, MEGACO, Communication, HTML, Human voice, Database, Left, PTT, Signal, TDM, Voice over IP, LTE, MGCP, Malicious caller identification, ETSI, 3GPP, Wireless, Report, SIGTRAN, ISDN, GSM, David Acord, PDF, Quality, Environment, Optics, MAP, CAS, Mobile phone

Customized for IP, Wireless, and TDM networks, this platform provides comprehensive solutions to fulfill your monitoring requirements in any environment.

Key Points: 
  • Customized for IP, Wireless, and TDM networks, this platform provides comprehensive solutions to fulfill your monitoring requirements in any environment.
  • GL's Network Surveillance System (NetSurveyorWeb™) is a web-based tool for monitoring and analyzing networks.
  • With support for multiple protocols and interfaces, NetSurveyorWeb™ enables network operators and service providers to improve network performance, diagnostics, and overall reliability.
  • It works with Delay Measurement tools to analyze captured voice traffic and provide precise one-way delay metrics
    Monitoring Air Traffic (ED-137) Network: Supports Air Traffic Network (ED-137) monitoring.